Paperwork Reduction Act of 1995, no person

TRANSMITTAL **FORM** 

(to be used for all correspondence after initial filing)

PTO/SB/21 (09-04) Approved for use through 07/31/2006. OMB 0651-0031

1		Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE llection of information unless it displays a valid OMB control number.				
	Application Number	10/088,138				
	Filing Date	November 25, 2002 Saliha MOUSSAOUI-MRABET et al.				
	First Named Inventor					
	Art Unit	1632				
	Examiner Name	FALK, Anne Marie				
	Attorney Docket Number	ST99040 US PCT				

Tota	al Number of	Pages in	This Submission	7	Attorney Docket Number	ST9904	10 US PC	Т	
ENCLOSURES (Check all that apply)									
	Fee Transmittal Form Fee Attached  Amendment/Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement  Certified Copy of Priority Document(s)				Drawing(s) Licensing-related Papers		片,	Арреа	Allowance Communication to TC  Il Communication to Board leals and Interferences
					Petition Petition to Convert to a Provisional Application Power of Attorney, Revoca Change of Correspondence Terminal Disclaimer Request for Refund CD, Number of CD(s) Landscape Table on	e Address		Appea Proprio Status Other pelow) Seque Seque Diske	al Communication to TC al Notice, Brief, Reply Brief) etary Information  Letter Enclosure(s) (please Identify :: ence Listing Statement ence Listing Printout tte containing Sequence Listing e to Comply
	Reply to Missing Parts/ Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53								
		•	SIGNA	TURE C	OF APPLICANT, ATT	ORNEY, C	OR AGE	NT	
Firm Name sanofi-aventis									
Signat	Signature Karen Karen								
Printed name Karen I. KRUPEN			V						
Date February 07, 2006				Reg. No.	34, 647	34, 647			
CERTIFICATE OF TRANSMISSION/MAILING									
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: (USPTO FAX NO; Total No. of Pages Transmitted: _7)									
Signature Dela Covable									
Typed or printed name Delia Coughlin				 า	0			Date	2/7/06

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



## **Notice to Comply**

Application No.	Applicant(s) Moussaoui-Mrabet et al.				
10/088,138					
Examiner	Art Unit				
Anne-Marie Falk, Ph.D.	1632				

## NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set in the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
  2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
  3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
  4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
  5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer
- and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☑ 7. Other: Sequences listed in the specification should be identified by a sequence identifier.

**Applicant Must Provide:** 

- An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- An initial or substitute paper copy of the "Sequence Listing", as well as an amendment specifically directing its entry into the specification.
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (571) 272-2510

For CRF Submission Help, call (571) 272-2501/2583.

Patentin Software Program Support

Technical Assistance......703-287-0200

To Purchase Patentin Software.....703-306-2600

ANNE-MARIE FALK, PH.D PRIMARY EXAMINER

nne-Marie Falk

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY